A relative gave me the Arthritis Research UK magazine and I found this article interesting, so thought I'd share. This could be positive news for us autoimmuners.
"New biological therapies for inflammatory arthritis continue to flood the market. With patents for the older anti-TNF-therapies, such as infliximab, due to expire in the next couple of years, a new class of cheaper, similar drugs will become available."
This part is also interesting:
"The first monoclonal antibody biosimilars have recently been licensed for use in the UK. Inflectra, marketed by Hospira and Remsima, manufactured by Celltrion, are essentially the same infliximab biosimilar of the original product Remicade, made by Johnson & Johnson. They have been approved by the EMA for the treatment of inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Although Inflectra and Remsima have been approved, a last minute extension of the original patent on Remicade means that they are now unlikely to be available in the UK before February 2015. When they finally hit the shelves, Inflectra and Remsima are predicted to be around 30% cheaper than the original drug. Another infliximab biosimilar, as well as several etanercept and rituximab biosimilars, are also currently in late stage clinical trials."
It also talks a bit about why some people do not respond to anti TNFs and research into finding genes and proteins that trigger the autoimmune responses, with the hope of moving towards a more individualised approach.